Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Dec

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers

Deb Schrag Elected 2027–2028 ASCO President

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns